Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of JNJ-61178104 in Healthy Subjects
NCT02758392Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2016
- Primary completion
- Jan 2017
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-61178104 in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants With Adverse Events Following Study Drug Administration at Day 113. Started Apr 2016; status: completed.
02
Drugs
JNJ-61178104
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02758392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02758392.